OGN Latest Press Releases

-- October 30, 2026 --

Organon Announces Quarterly Dividend Business Wire 8:25 AM

-- October 27, 2026 --

Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors Globe Newswire 8:00 AM

-- October 19, 2026 --

Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing Business Wire 7:30 AM

-- October 16, 2026 --

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting Business Wire 7:30 AM

-- October 1, 2026 --

Organon to Present New Real-World Analysis of VTAMA (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference Business Wire 8:00 AM

-- September 28, 2026 --

Organon Canada announces the Approval and Availability of NDUVRA (tapinarof cream), 1%, a New Steroid-Free Topical Treatment for Moderate to Severe Atopic Dermatitis in Adult and Pediatric Patients 2 Years of Age and Older PRNewswire 8:02 AM

-- September 14, 2026 --

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA, a Hormone-Free Intrauterine Device Business Wire 7:30 AM

-- August 27, 2026 --

National Can-RISE Study to Help Close Critical Gaps in Menopause Research Globe Newswire 9:00 AM

-- August 11, 2026 --

Organon Opens REMS Program for MIUDELLA Ahead of Anticipated Commercial Availability Business Wire 7:30 AM

-- July 31, 2026 --

Organon Announces Quarterly Dividend Business Wire 8:30 AM

-- July 24, 2026 --

New Analysis of Phase 3 Pooled Data for Organon's VTAMA (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1 Business Wire 8:00 AM

-- July 22, 2026 --

ORGANON CANADA ANNOUNCES THE APPOINTMENT OF DOMINIC BGIN AS PRESIDENT AND MANAGING DIRECTOR PRNewswire 8:02 AM

-- July 16, 2026 --

Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing Business Wire 7:30 AM

-- July 7, 2026 --

Organon to Present New Analysis on VTAMA (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting Business Wire 8:00 AM

-- June 25, 2026 --

Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders? PRNewswire 1:58 PM

-- June 24, 2026 --

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN Business Wire 2:28 PM

-- June 23, 2026 --

Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS (denosumab injection) and TUZEMTY (denosumab injection), Biosimilars to PROLIA and XGEVA Business Wire 5:30 AM

-- June 22, 2026 --

Organon Completes Agreement to License MIUDELLA, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device Business Wire 7:30 AM

-- June 18, 2026 --

Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA (ustekinumab), a Biosimilar Referencing STELARA (ustekinumab) in Canada Business Wire 6:00 AM

-- June 16, 2026 --

Halper Sadeh LLC is Investigating Whether LPRO, NUVL, OGN, SUNE are Obtaining Fair Deals for their Shareholders Globe Newswire 9:14 PM

-- June 10, 2026 --

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19 Business Wire 7:30 AM

-- June 9, 2026 --

Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders Globe Newswire 8:04 PM

Market Data Delayed 15 Minutes